Proactiveinvestors USA & Canada Lexaria Bioscience Corp https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Lexaria Bioscience Corp RSS feed en Sun, 21 Jul 2019 22:28:03 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Lexaria Bioscience is seeing increased demand for its DehydraTECH drug delivery system ]]> https://www.proactiveinvestors.com/companies/news/223829/lexaria-bioscience-is-seeing-increased-demand-for-its-dehydratech-drug-delivery-system-223829.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) is a Canadian company with a patented technology that promises to change the way drugs are delivered into the body.

The Kelowna, British Columbia-based company developed and markets DehydraTECH, which masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

In 2013, Lexaria’s management decided to pivot from oil to cannabis and within a year had acquired the rights to DeydraTECH, which is now the company’s main focus.

Essentially, DehydraTECH allows cannabidiol (CBD) and other oils to be dehydrated into an odourless, tasteless powder and mixed with xanthan gum, corn flour and other base ingredients which can then be added to foods, drinks and creams.

It also allows drugs and vitamins – in the case of cannabis, CBD – to enter the bloodstream faster than existing drug delivery platforms.

While cannabis is the main market right now, Lexaria is developing DehydraTECH for other markets as well, such as nicotine and painkillers called nonsteroidal anti-inflammatory drugs, or NSAIDs for short.

According to Lexaria’s CEO Chris Bunka, CBD-infused food and beverages treated with DehydraTECH taste better, smell better, work quicker and have a higher level of effectiveness.

Outlook

Recently a new version of the company’s DehydraTECH delivery platform has been developed.

Bunka says this new version provides significant improvements geared for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical and supplement markets, as well as for cannabis.

DehydraTECH 2.0 showed more than a 100% improvement over the original version in delivering CBD into the bloodstream in initial testing.

It also delivered an exceptional improvement of CBD into brain tissue as compared to standard industry formulations, meaning that Lexaria is starting to demonstrate the ability to deliver the API through the blood-brain barrier and into receptor cells.

Similar to other cannabis-involved companies, local laws will probably be a significant growth driver during the rest of 2019. Canada recently legalized CBD-infused edibles for sale in October, and across the border in the US, more states are also expected to follow the likes of Colorado and California to legalize recreational cannabis.

Revenue generation comes from a variety of licensee partners, from startup companies to Altria Corp, owners of the Marlboro cigarette brand. The tobacco giant invested up to US$12 million in Lexaria in January 2019 to help fund research and development of DedydraTECH. Altria will pay Lexaria Nicotine a royalty on revenue generated from the sale of nicotine products containing DehydraTECH™ and holds the option to acquire 100% ownership in Lexaria Nicotine.

In July, Lexaria entered into a partnership with Univeral Hemp LLC, which manufactures hemp-derived bulk ingredients to the nutraceutical and consumer packaged goods industries to use in CBD-based food ingredients. Universal Hemp plans to make its CBD-infused bulk food ingredients available throughout the USA immediately, and in Canada when regulations permit.

The deal will work under a royalty agreement, but the deal is worth a minimum of around US$3.75 million.

On the research and development front, Lexaria plans to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for its licensee partners. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to THC as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within Lexaria’s patent portfolio.

What the CEO says

CEO Bunka is Lexaria’s largest shareholder and its self-described trumpeter-in-chief.

“We can actually provide these ingredients, get it into the hands of consumers so that they can enjoy the products they already like," he said. 

“One of the things that makes Lexaria different is that we are international – we have current operations in Canada and the US, we’re in negotiations in Mexico and Europe. Our technology is a really powerful technology and it’s starting to really gain traction, especially in the US.”

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

]]>
Fri, 12 Jul 2019 08:50:00 -0400 https://www.proactiveinvestors.com/companies/news/223829/lexaria-bioscience-is-seeing-increased-demand-for-its-dehydratech-drug-delivery-system-223829.html
<![CDATA[Media files - Lexaria Bio Science signs 5-year deal to provide technology to Universal Hemp ]]> https://www.proactiveinvestors.com/companies/stocktube/14069/lexaria-bio-science-signs-5-year-deal-to-provide-technology-to-universal-hemp-14069.html Thu, 11 Jul 2019 16:32:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/14069/lexaria-bio-science-signs-5-year-deal-to-provide-technology-to-universal-hemp-14069.html <![CDATA[News - Lexaria Bioscience inks CBD license pact in US and Canada with Universal Hemp ]]> https://www.proactiveinvestors.com/companies/news/223755/lexaria-bioscience-inks-cbd-license-pact-in-us-and-canada-with-universal-hemp-223755.html Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX), a drug delivery platform company, revealed Thursday that it has inked a definitive five-year pact through its subsidiary Lexaria Hemp Corp with Universal Hemp LLC.

The Kelowna, British Columbia company will provide its patented DehydraTECHTM technology to Universal Hemp LLC, a manufacturer of hemp-based raw ingredients and CBD derivatives.

Universal Hemp plans to make its CBD-infused bulk food ingredients available in the US immediately, and in Canada when new legislation takes effect in October.

READ: Lexaria Bioscience inks CBD beverage license agreement in US with Nic's Beverages

The company did not disclose financial details, or royalty payment rates, although it did say that the companies have agreed to disclose minimum payments over the life of the agreement of US$3,750,000.

“We are very excited about signing this licensing agreement with Lexaria Bioscience to bring to market Lexaria’s highly effective delivery system which makes cannabidiol or hemp-derived CBD readily available in the human body,” said Universal Hemp founder CEO Chad Kahunahana.

Tech being applied to CBD at scale

Kahunahana noted that Lexaria’s technology was developed over many years for specified applications and is now, for the first time, being applied to CBD at scale.

“We anticipate our SuperBio Infusion line of ingredients will become the industry leader for CBD-infused health and beauty, food and beverage, wellness, athletic and other products where maximum performance is vital,” said Kahunahana. “In terms of bioavailability, shelf stability and taste this is the best performing technology in the market, hands down. Our corporate customers cannot wait to put our water-soluble solution into their products.”

DehydraTECH-enabled food ingredients are protected under Lexaria’s existing US patents and include CBD-infused wheat or corn flour, gum Arabic, whey protein, green tea, tapioca starch and many forms suitable for beverage and dietary supplement formulations.

Lexaria Bioscience has 40 patents pending around the world for disruptive drug delivery technologies. A patent for DehydraTECH, which improves the taste, smell, speed and absorption of compounds, has been granted in the US and Australia.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

“We are pleased to announce our new licensee Universal Hemp whose well respected presence in the hemp industry will enable our patented technology to have widespread use and distribution in high-performance products providing precision dosing, maximum strength, and rapid uptake,” said Lexaria Bioscience CEO Chris Bunka.

Universal Hemp plans to make its CBD-infused bulk food ingredients available in the US immediately, and in Canada when regulations permit.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

 

]]>
Thu, 11 Jul 2019 08:13:00 -0400 https://www.proactiveinvestors.com/companies/news/223755/lexaria-bioscience-inks-cbd-license-pact-in-us-and-canada-with-universal-hemp-223755.html
<![CDATA[Media files - Buds & Duds: Cannabis stocks continue to slump but Lexaria Bioscience shares shine on CBD beverage deal ]]> https://www.proactiveinvestors.com/companies/stocktube/14049/buds--duds-cannabis-stocks-continue-to-slump-but-lexaria-bioscience-shares-shine-on-cbd-beverage-deal-14049.html Wed, 10 Jul 2019 15:58:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/14049/buds--duds-cannabis-stocks-continue-to-slump-but-lexaria-bioscience-shares-shine-on-cbd-beverage-deal-14049.html <![CDATA[News - Buds & Duds: Cannabis stocks continue to slump but Lexaria Bioscience shares shine on CBD beverage deal ]]> https://www.proactiveinvestors.com/companies/news/223693/buds--duds-cannabis-stocks-continue-to-slump-but-lexaria-bioscience-shares-shine-on-cbd-beverage-deal-223693.html Cannabis stocks were faced with yet another tough day on Wednesday, after weeks of losses across North American markets.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, dropped 2% to 225.5 points on Wednesday. The Horizons Marijuana Life Sciences Index ETF was down 0.7% to C$17.70. The OTCQX Cannabis Index inched up 0.2% at 716.3 points.

Buds

Despite the overall lags, a number of stocks shone on Wednesday.

Lexaria Bioscience Corp (OTCMKTS:LXRP) (CSE:LXX) shares were on the rise after the drug delivery platform signed a five-year deal through its subsidiary Lexaria Hemp Corp with Nic's Beverages Ltd.

Shares were up 2% at C$1.04 in Toronto and up 2.4% at US$0.79 in New York. 

The company will provide its patented DehydraTECHTM technology to Nic's Beverages Ltd for making its CBD-infused beverages to be produced and sold in the US.

"We are currently in discussions with major wholesale houses and are looking to be in the market by the first of October," said Nic's Beverages CEO John Goodpasture. "DehydraTECH technology is perfect in allowing us to deliver CBD from hemp oil with zero impact on our cold brewed coffee's outstanding aroma or flavour. Nic's is extremely excited about our new product lines and our continued growth with Lexaria."

READ: Lexaria Bioscience inks CBD beverage license agreement in US with Nic's Beverages

Another stock gaining ground Wednesday was Martello Technologies Group Inc (CVE:MTLO) (OTCMKTS:DRKOF) up 21.8% at C$0.95 in Toronto and up 39.3% at US$0.71.

The firm has seen significant gains this week after recent rumours the Canadian technology company would benefit from former Canopy Growth Corp (NYSE:CGC) (TSE:WEED) co-founder Bruce Linton, who appears to be spending more time working on Martello. Linton is currently the co-chairman of Kanata, Ontario-based Martello and was its CEO till 2017.

Investors connected the dots after Linton appeared on multiple TV interviews sporting a Martello T-shirt to talk about his departure from Canopy, the company he founded, which is now the largest marijuana company in the world.

In an interview with Proactive, Martello Technologies' CEO John Proctor said he welcomed Linton's continued involvement in Martello.

WATCH: Canopy Growth ex-CEO shines a new-found spotlight on Martello Technologies

"The first thing he did was shine a spotlight on us," said Proctor. "We're this little tiny company hiding in the corner that's suddenly got the spotlight on us and people got to look at us, lift the lid and say 'hey, we think you're a bit undervalued'..."

"Since then, more people have looked at us and have recognized the potential. We've done all the right things. If you look at our two co-chairs, one is Bruce, the other is Terry Matthews, the guy who founded Mitel and Newbridge and Wales' first billionaire. There's a lot of horsepower on the board and on the executive team here as well."

READ: Canopy Growth’s loss is Martello Technologies gain as Bruce Linton’s focus shifts Duds

Leading the laggard list Wednesday was CannTrust Holdings Inc (TSE:TRST) (OTCMKTS:CNTTF), whose shares continued to drop after the firm was dinged by Health Canada for growing cannabis in five grow rooms that didn't have a licence to operate at its Pelham, Ontario facility. Health Canada is currently investigating. 

Shares dropped 11.8% at C$4.17 in Toronto and were down 11.7% at US$3.18 in New York.

Additionally, analysts from two major Canadian banks downgraded the stock, dramatically lowering price targets as a result of the news. Royal Bank of Canada downgraded the stock from outperform to perform, reducing the target price to C$5 from C$13 and Bank of Montreal analysts downgraded CannTrust from outperform to speculative, slashing the target price to C$6, from C$11. 

Other stocks losing ground Wednesday included TILT Holdings Inc (CSE:TILT) (OTCMKTS:SVVTF), which has had a tough few months after it recorded a US$500 million impairment charge in its 2018 annual results in early May.

The stock dropped 6.1% at US$0.69 in New York.

On Wednesday, the firm released a note to shareholders, saying it is in discussion with discussions with financing groups. 

"In terms of our financing initiatives, I can confirm that we have been in discussions with multiple interested financing parties in the past month, and I look forward to making an announcement of our go-forward capital partner(s) in the coming weeks," noted interim CEO Mark Scatterday, who took on the post less than two months ago. 

Scatterday said the cannabis company is working to fast-track the business towards profitability.

Contact Katie Lewis at katie@proactiveinvestors.com

]]>
Wed, 10 Jul 2019 10:53:00 -0400 https://www.proactiveinvestors.com/companies/news/223693/buds--duds-cannabis-stocks-continue-to-slump-but-lexaria-bioscience-shares-shine-on-cbd-beverage-deal-223693.html
<![CDATA[News - Lexaria Bioscience inks CBD beverage license agreement in US with Nic's Beverages ]]> https://www.proactiveinvestors.com/companies/news/223675/lexaria-bioscience-inks-cbd-beverage-license-agreement-in-us-with-nic-s-beverages-223675.html Lexaria Bioscience Corp (OTCMKTS:LXRP) (CSE:LXX), a drug delivery platform company, revealed Wednesday that it has inked a five-year pact through its subsidiary Lexaria Hemp Corp with Nic's Beverages Ltd.

The company will provide its patented DehydraTECHTM technology to Nic's Beverages Ltd for making its CBD-infused beverages to be produced and sold in the United States.

The new license is the fourth beverage license awarded by Lexaria, three of which are for immediate use in the US and one in Canada pending new legislation taking effect in October.

READ: Lexaria Bioscience springs for digital marketing services from the Richmond Club

Nic's Beverages will initially begin production of ready-to-drink cold brew coffees enhanced with CBD from multi spectrum hemp oil.

"We are currently in discussions with major wholesale houses and are looking to be in the market by the first of October," said Nic's Beverages CEO John Goodpasture. "DehydraTECH technology is perfect in allowing us to deliver CBD from hemp oil with zero impact on our cold brewed coffee's outstanding aroma or flavour. Nic's is extremely excited about our new product lines and our continued growth with Lexaria."

Lexaria Bioscience is a Kelowna, British Columbia company with 40 patents pending around the world for disruptive drug delivery technologies. A patent for DehydraTECH, which improves the taste, smell, speed and absorption of compounds, has been granted in the US and Australia.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

Nic's Beverages was founded by a father and son team with a love for good coffee. The cold brew coffee is infused with CBD in four flavors.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Wed, 10 Jul 2019 07:29:00 -0400 https://www.proactiveinvestors.com/companies/news/223675/lexaria-bioscience-inks-cbd-beverage-license-agreement-in-us-with-nic-s-beverages-223675.html
<![CDATA[News - Lexaria Bioscience springs for digital marketing services from the Richmond Club ]]> https://www.proactiveinvestors.com/companies/news/223427/lexaria-bioscience-springs-for-digital-marketing-services-from-the-richmond-club-223427.html Lexaria Bioscience Corp (OTCMKTS:LXRP) (CSE:LXX), a drug delivery platform company, has decided to invest in media services for at least the next six months..

Streetwise Investors Club Inc, a Toronto-based company doing business under the name the Richmond Club, will help Lexaria with investor presentations, articles and videos, and other digital marketing services.

READ: Lexaria Bioscience shareholders approve the appointment of four directors

The deal will pay Richmond Club C$3,500 per month for a minimum of six months and will automatically be renewed unless terminated.

Lexaria Bioscience is a Kelowna, British Columbia company with 40 patents pending around the world for disruptive drug delivery technologies. A patent for DehydraTECH, which improves the taste, smell, speed and absorption of compounds, has been granted in the US and Australia.

Its shares slid 3.5% to C$1.09 on the CSE and 3.5% to US$0.84 on OTC Markets on Friday.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

]]>
Fri, 05 Jul 2019 08:25:00 -0400 https://www.proactiveinvestors.com/companies/news/223427/lexaria-bioscience-springs-for-digital-marketing-services-from-the-richmond-club-223427.html
<![CDATA[News - Lexaria Bioscience shareholders approve the appointment of four directors ]]> https://www.proactiveinvestors.com/companies/news/222611/lexaria-bioscience-shareholders-approve-the-appointment-of-four-directors-222611.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) reported a successful annual general meeting Friday, noting all matters were approved, including the appointment of four directors. 

The firm said directors appointed included: Chris Bunka, John Docherty, Nicholas Baxter and Ted McKechnie. The firm noted Davidson & Company LLP has been appointed as auditor. 

READ: Lexaria Bioscience crafts new DehydraTECH innovation, files patents

The firm noted shareholders also approved executive compensation.

Lexaria has developed and out-licenses its delivery technology, which promotes healthier ingestion methods and lower overall dosing. Its DehydraTECH technology is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time. The firm acquired its technology in 2014. 

Lexaria's technology provides boosts in intestinal absorption rates and more rapid bloodstream delivery for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The firm has patents pending in more than 40 countries.

Shares of Lexaria Bioscience were at C$1.10 on Friday. 

Contact Katie Lewis at katie@proactiveinvestors.com

]]>
Fri, 21 Jun 2019 13:06:00 -0400 https://www.proactiveinvestors.com/companies/news/222611/lexaria-bioscience-shareholders-approve-the-appointment-of-four-directors-222611.html
<![CDATA[Media files - Lexaria Bioscience formulates enhanced DehydraTECH for more efficient cannabis delivery ]]> https://www.proactiveinvestors.com/companies/stocktube/13683/lexaria-bioscience-formulates-enhanced-dehydratech-for-more-efficient-cannabis-delivery-13683.html Mon, 10 Jun 2019 10:36:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/13683/lexaria-bioscience-formulates-enhanced-dehydratech-for-more-efficient-cannabis-delivery-13683.html <![CDATA[News - Lexaria Bioscience crafts new DehydraTECH innovation, files patents ]]> https://www.proactiveinvestors.com/companies/news/221475/lexaria-bioscience-crafts-new-dehydratech-innovation-files-patents-221475.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) revealed Tuesday that a new version of the company’s DehydraTECH delivery platform provides "significant improvements" initially geared for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical and supplement markets.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The Kelowna, British Columbia company's use of a “naturally sourced formulation enhancement” more than doubles DehydraTECH's absorption performance, said Lexaria in a statement, indicating that it has filed a new patent application linked to the innovation.

READ: Lexaria’s DehydraTECH combined with nanotech techniques delivers more CBD into brain tissue by over tenfold

On March 20, Lexaria started running animal tests with multiple objectives that included evaluating enhanced DehydraTECH formulations that might offer better performance. 

In this arm of the animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhanced gastro-intestinal absorption.

Test results

In the study, 10 male Sprague-Dawley rats were administered identically sourced CBD at a rate of 25 milligram per kilogram of bodyweight.

Delivery of CBD into the bloodstream was measured at 2, 4, 6, 8, 12, 15, 30, 45, and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.

On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (MCT) coconut-oil formulation 15 minutes after dosing.

On Tuesday, the company reports that enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations; and 110% more CBD into blood than DehydraTECH in its traditional format.

Here are the main findings:

Enhanced DehydraTECH delivered roughly twice as much CBD to animal blood at all measured time points in the study from the 15-minute mark onwards, compared to traditional DehydraTECH; and during the same time points from 717% to 1098% more CBD than the generic industry MCT coconut oil formulations Enhanced DehydraTECH delivered more CBD to blood in just 12 minutes than the MCT coconut-oil formulation was able to achieve at any point during the one hour test duration. Enhanced DehydraTECH is even faster acting, reaching a maximum blood concentration level in just 45 minutes compared to traditional DehydraTECH at 50 minutes and the MCT coconut oil formulation at 57 minutes. Enhanced DehydraTECH delivered 1,937% more CBD into animal brain tissues after 8 hours compared to generic industry MCT coconut oil formulations; and 487% more than traditional DehydraTECH.

Both traditional DehydraTECH and enhanced DehyraTECH delivered maximum blood-concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter.

The DehydraTECH technology demonstrates both fast onset and fast offset, which is of interest for repeated dosing.

New drug delivery performance thresholds

DehydraTECH's in its traditional format has been used commercially since 2014 and by technology licensees since 2016.

Lexaria has introduced innovations for oral cannabis formats such as capsules, beverages and edibles. DehydraTECH has been equally useful in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.

Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies.

With this new innovation, the company is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations, said Lexaria.

More studies

The company is planing more studies this year to characterize enhanced DehydraTECH and optimize it into product applications for its licensees.

The specific nature of enhanced DehydraTECH was undisclosed for proprietary reasons until the new patent filings are published.

Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds named in the Lexaria patent suite.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Tue, 04 Jun 2019 07:45:00 -0400 https://www.proactiveinvestors.com/companies/news/221475/lexaria-bioscience-crafts-new-dehydratech-innovation-files-patents-221475.html
<![CDATA[News - Lexaria’s DehydraTECH combined with nanotech techniques delivers more CBD into brain tissue by over tenfold ]]> https://www.proactiveinvestors.com/companies/news/221053/lexarias-dehydratech-combined-with-nanotech-techniques-delivers-more-cbd-into-brain-tissue-by-over-tenfold-221053.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) revealed Tuesday that animal tests show the company’s DehydraTECH technology combined with generic nanotech techniques delivers more than ten times the amount of cannabidiol (CBD) to the brain.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The Kelowna, British Columbia company’s disruptive DehydraTECH technology can be applied to foods, beverages, oral suspensions, tablets and capsules.

DehydraTECH with generic nanotech techniques now delivers 1,137% more CBD into animal brain tissues, said the company in a statement following oral ingestion than other existing industry formulations.

READ: Lexaria’s DehydraTECH formulation delivers CBD to bloodstream quicker than conventional industry formulations

On March 20, Lexaria started running animal tests with multiple objectives that included developing a better understanding of how effectively edible forms of CBD cross the blood-brain-barrier.

In this arm of the study, Lexaria combined its DehydraTECH delivery technology with standard nanotechnology to analyze how quickly CBD was delivered into an animal’s brain tissues following oral ingestion.

Lexaria earlier carried out two series of animal tests in 2018 that proved that its DehydraTECH delivers nicotine across the blood-brain-barrier more effectively than industry standards. This new study seeks to build on the premise whether this holds true for cannabinoids. Derived from hemp, CBD does not contain the psychoactive compounds found in cannabis.

Lexaria also tested for differences in brain delivery rates between its patented long chain fatty acid CBD formulations without nanotech processing with those of medium chain triglycerides (MCT) oils.

Encouraging test results

In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were orally administered CBD at the rate of 25 milligram per kilogram of bodyweight. Delivery of CBD into the brain was reported 8 hours after dosing.

In working with nanoemulsion processing equipment, Lexaria has developed a method to combine DehydraTECH with nanoemulsification for specific performance applications. Lexaria does not work with inorganic materials for purposes of nano-transformation since inorganic materials manipulated with nanotech have at times indicated poor health outcomes in animal testing. Lexaria's patented formulations rely solely on safe organic ingredients.

Lexaria’s DehydraTECH long chain fatty acid formulation without nanotech achieved an average brain tissue accumulation level that was 246% higher than the average for those animals that received the MCT oil formulation.

On the other hand, the DehydraTECH long chain fatty acid formulation with nanotech achieved an average brain tissue accumulation level that was 1,137% higher than the average for those animals that received the MCT oil formulation.

Positive conclusion

A series of animal tests conducted in 2018 and 2019 have already shown DehydraTECH to greatly assist the delivery of nicotine and cannabinoids across the blood-brain-barrier.

The effectiveness of DehydraTECH together with nanoemulsification now greatly expands the applicability of Lexaria’s technology both for conventional edible dosage, consumable liquid and beverage dosage forms.

The company said it will make its new technological advances available to its licensed corporate clients in North America through license agreements as rapidly as it is possible to customize each unique client formulation.

Lexaria said its wholly owned subsidiary Lexaria Pharmaceutical will pursue the technology’s opportunities outside of cannabinoids and nicotine to encompass other drug classes.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Tue, 28 May 2019 09:13:00 -0400 https://www.proactiveinvestors.com/companies/news/221053/lexarias-dehydratech-combined-with-nanotech-techniques-delivers-more-cbd-into-brain-tissue-by-over-tenfold-221053.html
<![CDATA[News - Lexaria Bioscience, Nuka Enterprises expand relationship to rapidly grow market for Nuka’s 1906 edibles brand ]]> https://www.proactiveinvestors.com/companies/news/220696/lexaria-bioscience-nuka-enterprises-expand-relationship-to-rapidly-grow-market-for-nukas-1906-edibles-brand-220696.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) announced Tuesday that the “most reliable, fast-acting edibles” on the market will now be available across the country through a major expansion in operations by Nuka Enterprises LLC, maker of 1906 cannabis edibles for adults.

Last year, Nuka acquired contractual options to expand its use of Lexaria’s DehydraTECH technology which delivers cannabinoids (CBD) to the bloodstream more quickly and effectively than conventional industry CBD edible formulations.

Exercising some of those options, Nuka plans to expand operations for cannabis chocolates and edibles in six additional states and cannabis beverages in three states in 2019 and 2020.

READ: Lexaria’s DehydraTECH formulation delivers over tenfold CBD to bloodstream than conventional industry formulations

“As the fastest growing edibles brand in Colorado, we believe a huge part of our consumer appeal is because of this fast-acting technology,” said Nuka Enterprises co-founder and CEO Peter Barsoom in a statement. “We look forward to continuing to innovate alongside Lexaria, whose technology is the best in the industry.”

Currently, 1906 offers six distinct formulations that combine low-dose cannabis with targeted plant medicines. Over the next two years, 1906 is expanding its product offerings to other legal markets including: Illinois, Ohio, Massachusetts, and Michigan. Overall, roughly a ten-fold increase in product volumes manufactured by Nuka utilizing DehydraTECH is expected over the next 18 months.

As part of its mission to bring cannabis back to its pre-prohibition status as widely used medicine, Nuka says it will also begin using DehydraTECH to create consumer products containing CBD.

Breakthough CBD technology

Lexaria’s DehydraTECH formulation delivers over a tenfold amount of CBD to the bloodstream than conventional industry formulations.

The company recently announced that animal testing proved its flagship DehydraTECH technology delivers 475% more CBD to the bloodstream in 15 minutes than other standard industry formulations that combine CBD with medium chain triglyceride (MCT) oils such as coconut oil.

Nuka has utilized Lexaria’s technology within its award-winning 1906 chocolates for roughly three years. Since its founding three years ago, 1906 has advanced from a start-up to Colorado’s fastest growing edibles company, whose products are now available in more than 200 dispensaries.

Semi-exclusive agreement

The semi-exclusive agreement provides Nuka and 1906 with competitive technological advantages until 2028, as well as growing revenue streams for Lexaria. A second license provides Nuka and 1906 with the immediate ability to utilize DehydraTECH technology for CBD across the US marketplace.

“Nuka’s astonishing growth since launch is impressive and we can’t wait to see what innovative products they design next using DehydraTECH technology,” said Lexaria Bioscience CEO Chris Bunka. “Together, we have a market advantage that will significantly change public perception of how and when to consume cannabis and plant medicine because consumers don’t have to wait an hour, or longer for their edibles to kick in with the 1906 brand.”

On April 30, 2018, Lexaria announced that Nuka had also acquired an option to expand its products and brand to Canada and across the US. Nuka and 1906 plan to leverage the competitive advantages of Lexaria’s DehydraTECH across multiple product lines including edibles and topical products.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The Kelowna, British Columbia-based company’s disruptive DehydraTECH technology can be applied to foods, beverages, oral suspensions, tablets and capsules.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Tue, 21 May 2019 07:44:00 -0400 https://www.proactiveinvestors.com/companies/news/220696/lexaria-bioscience-nuka-enterprises-expand-relationship-to-rapidly-grow-market-for-nukas-1906-edibles-brand-220696.html
<![CDATA[News - Lexaria’s DehydraTECH formulation delivers over tenfold CBD to bloodstream than conventional industry formulations ]]> https://www.proactiveinvestors.com/companies/news/220311/lexarias-dehydratech-formulation-delivers-over-tenfold-cbd-to-bloodstream-than-conventional-industry-formulations-220311.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) announced Wednesday that animal testing proved the company’s DehydraTECH technology delivers cannabinoids (CBD) to the bloodstream “more quickly and effectively” than conventional industry CBD edible formulation designs that combine CBD with medium chain triglyceride (MCT) oils such as coconut oil.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The Kelowna-headquartered company’s disruptive DehydraTECH technology can be applied to foods, beverages, oral suspensions, tablets and capsules.

READ: Lexaria Bioscience gains after announcing cannabinoid R&D project is underway

On March 20, Lexaria started a series of animal studies with multiple objectives, including gaining a better understanding of how edible forms of cannabinoids enter the bloodstream.

In the first animal study, Lexaria compared its standard DehydraTECH formulation that combines cannabinoids with long-chain fatty acids (LCFA) using Lexaria's patented dehydration processing technique to a concentration-matched formulation utilizing coconut oil which is a commonly used MCT oil in the cannabis edibles industry.

Lexaria has consistently postulated that the use of MCT oil in edibles is less effective for purposes of cannabinoid delivery optimization than its patented DehydraTECH LCFA formulations.

In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered CBD at 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was monitored over a 60-minute duration.

Test results showed

• The DehydraTECH formulation delivered measurable quantities of cannabidiol into the bloodstream in as little as two minutes

• Lexaria's technology delivered more CBD to the bloodstream in 15 minutes than conventional medium chain triglyceride (MCT) oil-based control formulations did in 60 minutes

• The area under the curve (AUC) for Lexaria's patented DehydraTECH formulation was 389% more than the MCT oil control formulation

• Lexaria's DehydraTECH formulation delivers cannabinoids at industry-leading volumes and speed while effectively masking bitter flavor and aroma profiles

Although the studies tested only for CBD delivery, Lexaria said it has “every reason to believe that virtually identical results would have been achieved” if THC was instead the cannabinoid under examination, consistent with subjective human clinical studies Lexaria's partners have conducted with edible THC products.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Wed, 15 May 2019 07:52:00 -0400 https://www.proactiveinvestors.com/companies/news/220311/lexarias-dehydratech-formulation-delivers-over-tenfold-cbd-to-bloodstream-than-conventional-industry-formulations-220311.html
<![CDATA[News - Lexaria Bioscience inks US partnership to produce CBD beverages ]]> https://www.proactiveinvestors.com/companies/news/219801/lexaria-bioscience-inks-us-partnership-to-produce-cbd-beverages-219801.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) is dishing out its signature infusion technology to build a better cannabidiol beverage.

Through its subsidiary Lexaria Hemp Corp, the company is pairing its DehydraTECH system with a Nevada-based private company to create CBD beverages for sale in the US.

DehydraTECH is the company’s method of delivering anything from vitamins to nicotine to CBD in order to maximize absorption, speed and taste.

READ: Lexaria Bioscience welcomes four new experts to advisory board to guide ongoing research

The deal is expected to last five years, although no financial details nor the company’s name, was disclosed.

The Kelowna, British Columbia company also announced it would issue 790,000 stock options to directors, an offer and its employees at an exercise price of C$0.99 per share.

Lexaria is focused on developing healthier ingestion methods and fast-acting, pleasant-tasting products. DehydraTECH is patented in the US and Australia, and the company has patents pending in 40 countries.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

]]>
Tue, 07 May 2019 08:30:00 -0400 https://www.proactiveinvestors.com/companies/news/219801/lexaria-bioscience-inks-us-partnership-to-produce-cbd-beverages-219801.html
<![CDATA[News - Lexaria Bioscience welcomes four new experts to advisory board to guide ongoing research ]]> https://www.proactiveinvestors.com/companies/news/219108/lexaria-bioscience-welcomes-four-new-experts-to-advisory-board-to-guide-ongoing-research-219108.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) has added four experts to its scientific advisory board to guide the firm's ongoing and future R&D (research and development) programs.

The Kelowna-headquartered company has developed and out-licenses its disruptive DehydraTECH technology that promotes lower dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

READ: Lexaria Bioscience gains after announcing cannabinoid R&D project is underway

Essentially, the tech allows cannabidiol (CBD) and other oils to be dehydrated into an odourless, tasteless powder and mixed into other substances.

Dr. Dwayne Godwin is a neuroscientist with extensive experience in the pharmacology of the brain and translational interests in the physiological basis and neuroimaging of brain injury, alcohol abuse, epilepsy and seizure, Alzheimer's and PTSD (post-traumatic stress disorder).

Meanwhile, Dr. Terry Blumenthal is professor, psychology and neuroscience, at Wake Forest University in North Carolina. His research interests include psychophysiology, research design and methodology, PTSD, information processing, schizophrenia, and developmental neuroscience.

Dr. Matthew Fraser has extensive experience in urological and gastrointestinal neuroscience preclinical research, development of research models and methods, experimental design, and early clinical development in both academic and industry settings.

Finally, Dr. Carla Lema Tome is an industry consultant and is widely published on topics including but not limited to cellular and molecular neuroscience, inflammation, neurodegeneration, and cancer biology.

Extensive experience

She has extensive experience in global medical and commercial strategy consulting with emphasis on integrated clinical development, asset and portfolio strategy, launch planning payer research and payer value communications

"Lexaria Bioscience Corp is very pleased to welcome these accomplished experts to our advisory board, who can provide critical scientific guidance to Lexaria's ongoing and future R&D programs," said Chris Bunka, CEO at Lexaria.

"Lexaria is building towards becoming one of the world's leaders in drug delivery technology and our most recent Advisors can assist in achieving that goal."

Contact Giles at giles@proactiveinvestors.com

Follow him on Twitter@Gile74

]]>
Thu, 25 Apr 2019 07:46:00 -0400 https://www.proactiveinvestors.com/companies/news/219108/lexaria-bioscience-welcomes-four-new-experts-to-advisory-board-to-guide-ongoing-research-219108.html
<![CDATA[News - Lexaria Bioscience Corp announces beverage license deal with California cannabis company ]]> https://www.proactiveinvestors.com/companies/news/219065/lexaria-bioscience-corp-announces-beverage-license-deal-with-california-cannabis-company-219065.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), announced Wednesday that it has inked an agreement via subsidary Lexaria CanPharm ULC to provide its Dehydratech technology to a private California-based cannabis company for use in certain cannabis-based beverages, which will be produced and sold in California and Nevada. 

The Kelowna-headquartered company said in a release that financial terms of the agreement will not be disclosed and the definitive agreement is for five years. 

The Dehydratech-enabled beverages are protected under Lexaria's existing US-granted patents and may include any combination of ready-to-drink beverages such as non-alcoholic beers, wines and spirits; cold or hot coffee or teas, sports drinks and more.

READ: Lexaria Bioscience renews CEO Chris Bunka and President John Docherty's contracts

Lexaria's technology, Dehydratech, allows cannabidiol (CBD) and other oils to be dehydrated into an odorless, tasteless powder and mixed with xanthan gum, corn flour and other base ingredients which can then be added to foods, drinks and creams.

"Lexaria is currently experiencing unprecedented demand in several North American markets for use of its technology for beverage applications," noted the company in the release. 

Lexaria has multiple patents pending in over 40 countries and already has patents in the US and in Australia for Dehydratech.

Shares of Lexaria were at C$1.36 on Wednesday. 

Contact Katie Lewis at katie@proactiveinvestors.com

 

]]>
Wed, 24 Apr 2019 17:48:00 -0400 https://www.proactiveinvestors.com/companies/news/219065/lexaria-bioscience-corp-announces-beverage-license-deal-with-california-cannabis-company-219065.html
<![CDATA[News - Lexaria Bioscience renews CEO Chris Bunka and President John Docherty's contracts ]]> https://www.proactiveinvestors.com/companies/news/218238/lexaria-bioscience-renews-ceo-chris-bunka-and-president-john-docherty-s-contracts-218238.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), the cannabis company, announced Tuesday that it has successfully renewed the management contracts for both its CEO Chris Bunka and its President John Docherty.

The new contracts last for three years and will allow the Kelowna, British Columbia-based company to make sure its senior team stays in place at a time when its business is growing considerably.

READ: Lexaria Bioscience announces optimistic new trial results for its hemp oil capsule TurboCBD

In other news, Lexaria also said it has reached agreements to cancel 1.14 million stock options with exercise prices ranging from US$0.10 to US$2.06.

The backbone of Lexaria’s business is a technology called Dehydratech. Essentially, it allows cannabidiol (CBD) and other oils to be dehydrated into an odorless, tasteless powder and mixed with xanthan gum, corn flour and other base ingredients which can then be added to foods, drinks and creams.

Lexaria has multiple patents pending in over 40 countries and already has patents in the US and in Australia for Dehydratech.

Lexaria shares slipped C$0.09 to hit C$1.43 on Tuesday.

-- This story is updated to reflect latest share price movement -- 

Contact Ellen Kelleher at ellen@proactiveinvestors.com

 

 

]]>
Tue, 09 Apr 2019 07:57:00 -0400 https://www.proactiveinvestors.com/companies/news/218238/lexaria-bioscience-renews-ceo-chris-bunka-and-president-john-docherty-s-contracts-218238.html
<![CDATA[News - Lexaria Bioscience gains after announcing cannabinoid R&D project is underway ]]> https://www.proactiveinvestors.com/companies/news/216876/lexaria-bioscience-gains-after-announcing-cannabinoid-rd-project-is-underway-216876.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) climbed Wednesday after announcing that its largest-ever cannabinoid research and development project is underway.

This project will test for a variety of potential performance-enhancing variations of the company's DehydraTECH delivery technology.

Shares of Lexaria advanced C$0.03 to C$1.65 in Wednesday’s Canadian trading. They traded at US$1.21 on the OTC Markets.

READ: Lexaria Bioscience cites FDA statement on nicotine replacement therapy to help smokers quit

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

Lexaria’s approach can be applied to foods, beverages, oral suspensions, tablets and capsules.

In addition, the R&D program will for the first time ever evaluate DehydraTECH in combination with nanotech emulsion formulas evaluated last year, according to Lexaria.

Comparable studies

The program is made up of 11 separate animal studies, each of which is comparable in scope to individual animal studies conducted in 2018.

Separately, the Kelowna, British Columbia, company said it has terminated a license agreement between Lexaria CanPharm ULC and NeutiSci International Inc (CVE:NU) (OTCMKTS:NRXCF), announced in February 2018.

Last month, Lexaria cited a Food and Drug Administration statement on the development of safe and effective nicotine replacement therapies to help smokers quit cigarettes.

In January, a unit of Lexaria entered into a definitive agreement with Altria Group Inc (NYSE:MO) to fund research on regulatory compliant, oral forms of nicotine delivery.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

]]>
Wed, 20 Mar 2019 13:54:00 -0400 https://www.proactiveinvestors.com/companies/news/216876/lexaria-bioscience-gains-after-announcing-cannabinoid-rd-project-is-underway-216876.html
<![CDATA[News - Lexaria Bioscience cites FDA statement on nicotine replacement therapy to help smokers quit ]]> https://www.proactiveinvestors.com/companies/news/215336/lexaria-bioscience-cites-fda-statement-on-nicotine-replacement-therapy-to-help-smokers-quit-215336.html Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) cited on Tuesday a Food and Drug Administration statement on the development of safe and effective nicotine replacement therapies to help smokers quit cigarettes.

The Kelowna, British Columbia-based firm said it was working with a "world-leading tobacco company" to develop ingestible delivery of nicotine.

Positive results of this research and development program could provide nicotine products that meet the goals of the FDA, Lexaria said in a statement Tuesday. The company added that it will earn royalties on products sold by its tobacco partner that use its DehydraTECH delivery technology.

READ: Lexaria Bioscience inks deal with Altria Ventures to develop reduced-risk nicotine products

FDA Commissioner Scott Gottlieb said in a February 21 statement cited by Lexaria that nicotine replacement therapy is generally considered "to double the likelihood of a successful quit attempt.”

Lexaria said its technology could offer a method of delivering nicotine that preserves consumer choice, avoids the most serious health consequences of smoking cigarettes and harmonizes with current FDA policies.

The technology, according to the company, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

In January, a unit of Lexaria entered into a definitive agreement with Altria Group Inc (NYSE:MO) to fund the research and development of Lexaria's patented DehydraTECH technology.

Shares of Lexaria rose 1.7% to C$1.84 in Monday’s Canadian trading. They climbed 2.2% to US$1.41 on the OTC Markets.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

]]>
Tue, 26 Feb 2019 08:34:00 -0500 https://www.proactiveinvestors.com/companies/news/215336/lexaria-bioscience-cites-fda-statement-on-nicotine-replacement-therapy-to-help-smokers-quit-215336.html
<![CDATA[Media files - Lexaria Bioscience sees positive results from study using DehydraTECH Technology ]]> https://www.proactiveinvestors.com/companies/stocktube/12329/lexaria-bioscience-sees-positive-results-from-study-using-dehydratech-technology-12329.html Fri, 22 Feb 2019 12:18:00 -0500 https://www.proactiveinvestors.com/companies/stocktube/12329/lexaria-bioscience-sees-positive-results-from-study-using-dehydratech-technology-12329.html <![CDATA[News - Lexaria Bioscience announces optimistic new trial results for its hemp oil capsule TurboCBD ]]> https://www.proactiveinvestors.com/companies/news/215051/lexaria-bioscience-announces-optimistic-new-trial-results-for-its-hemp-oil-capsule-turbocbd-215051.html Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX) alerted investors on Thursday to a series of optimistic findings from a 2018 European study evaluating TurboCBD, its Dehydratech-powered cannabidiol (CBD) fortified hemp oil capsule.

Results from the study reveal that a single 90mg dose of TurboCBD showed evidence of lower blood pressure; higher blood flow to the brain; faster delivery of CBD into the bloodstream and larger quantities of CBD within the blood when measured against a single 90mg dose of generic CBD.

The study also suggested that Lexaria’s Dehydratech technology allows for better cannabinoid delivery upon ingestion.

READ: Lexaria Bioscience inks deal with Altria Ventures to develop reduced-risk nicotine products; shares soar

As part of the trial 90mg  dose of Lexaria’s TurboCBD was compared to the effects of a 90mg CBD dose without Lexaria’s Dehydratech technology (the positive control) as well as a placebo.

And analysis when CBD was at peak blood levels, thanks to Lexaria’s TurboCBD using DehydraTECH, showed a significant reduction in mean arterial blood pressure (MAP) compared to both the placebo and the generic CBD. This result highlights the usefulness of Lexaria's technology to allow for CBD to reduce blood pressure.

READ: Lexaria Bioscience: The cannabis company developing a potentially life-saving technology

“The findings that Lexaria’s Dehydratech technology can enable superior cannabinoid delivery are unique in this healthy-human clinical trial,” said Dr Phlip Ainslie, principal investigator and co-director of the Centre for Heart, Lung and Vascular Health at UBC Okanagan Campus, Kelowna, Canada. “Establishing the impact of CBD delivery on the health of the circulatory systems, including the brain, could have major implications for the adjunct treatment of high blood pressure and some neurological diseases.”

On the back of the study, Lexaria intends to conduct further clinical investigations within the next year using Dehydratech for cannabinoids with an expanded number of subjects over a more varied age range. Additional data and reports will be provided from future studies as they become available.

Based in Kelowna, British Columbia, Lexaria has developed and licenses out its disruptive delivery technology which increases intestinal absorption rates and offers more rapid delivery to the bloodstream. Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker.

Lexaria shares slipped 2% to finish at C$1.94 on Wednesday.

Contact Ellen Kelleher at ellen@proactiveinvestors.com 

]]>
Thu, 21 Feb 2019 08:00:00 -0500 https://www.proactiveinvestors.com/companies/news/215051/lexaria-bioscience-announces-optimistic-new-trial-results-for-its-hemp-oil-capsule-turbocbd-215051.html
<![CDATA[Media files - Lexaria Bioscience announces partnership with U.S. giant Altria to fund R&D ]]> https://www.proactiveinvestors.com/companies/stocktube/11856/lexaria-bioscience-announces-partnership-with-us-giant-altria-to-fund-rd-11856.html Tue, 15 Jan 2019 15:06:00 -0500 https://www.proactiveinvestors.com/companies/stocktube/11856/lexaria-bioscience-announces-partnership-with-us-giant-altria-to-fund-rd-11856.html <![CDATA[News - Lexaria Bioscience inks deal with Altria Ventures to develop reduced-risk nicotine products; shares soar ]]> https://www.proactiveinvestors.com/companies/news/212628/lexaria-bioscience-inks-deal-with-altria-ventures-to-develop-reduced-risk-nicotine-products-shares-soar-212628.html Cannabinoid-focused Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) is adding to its roster with a new partnership deal with venture capital firm Altria Ventures aimed at developing reduced-risk nicotine consumer products.

The company said the partnership will focus on using Lexaria's Bioscience's proprietary DehydraTECH™ platform, which allows cannabidiol (CBD) and other oils to be dehydrated into an odorless, tasteless powder.

DehydraTECH also allows drugs and vitamins – in the case of cannabis, CBD – to get into the bloodstream quicker.

Shares of Lexaria Bioscience jumped Tuesday, up 25% at C$2.10 in Toronto.

READ: Lexaria Bioscience: The cannabis company developing a potentially life-saving technology

"Lexaria Bioscience is proud that, after careful selection, Altria has chosen to fund research into DehydraTECH™ technology and potentially commercialize this technology for oral nicotine," said Chris Bunka, CEO of Lexaria Bioscience, in a statement.

"This partnership will provide significant benefits to Lexaria Bioscience and its shareholders with a world-class R&D Program and regulatory compliance process. We believe Altria is the best corporate partner we could work with to truly make a difference in the lives of millions of consumers."

Agreement terms

Under the terms of the agreement, Altria has been granted exclusive DehydraTECH license rights to commercialize oral nicotine products in the US.

Altria will fund a research & development program in exchange for a minority equity interest in Lexaria Nicotine and certain DehydraTECH(™) license rights. Altria will provide initial funding of US$1 million, with the option for additional funding of up to US$12 million through multiple phased private financings.

The company said Altria will initially have the right to appoint one of the seven directors on Lexaria Nicotine's board of directors and, through the additional phased investments, may have the right to appoint up to three of the seven directors.

The company added that Altria has the option to acquire 100% ownership interest in Lexaria Nicotine commensurate with fair market value. Lexaria Bioscience has not sold or optioned any of its own equity.

'Powerful' patented DehydraTECH technology

"Lexaria Bioscience has repeatedly demonstrated the powerful effects of its patented DehydraTECH(™) technology for enhancing the palatability and speed of onset of orally-consumed bioactive substances such as nicotine," said John Docherty, president of Lexaria Bioscience.

"Laboratory research to date on oral nicotine formulations has been quite encouraging. We are very excited to advance the clinical phases of our comprehensive R&D Program together with Altria with a view to full commercial product development."

 

Contact Katie Lewis at katie@proactiveinvestors.com
Follow her on Twitter: @kelewis

]]>
Tue, 15 Jan 2019 12:27:00 -0500 https://www.proactiveinvestors.com/companies/news/212628/lexaria-bioscience-inks-deal-with-altria-ventures-to-develop-reduced-risk-nicotine-products-shares-soar-212628.html
<![CDATA[News - Lexaria Bioscience: The cannabis company developing a potentially life-saving technology ]]> https://www.proactiveinvestors.com/companies/news/210241/lexaria-bioscience-the-cannabis-company-developing-a-potentially-life-saving-technology-210241.html It’d be easy to dismiss a company which pivots away from oil and gas towards cannabis as one which has jumped on the bandwagon to take advantage of what is now a booming industry.

But not Lexaria Bioscience Corp (CNSX:LXX), which made its move into cannabis back in 2013 before it was trendy.

WATCH: Lexaria continues to show success after restructuring

At the time, it owned a producing oil field in Mississippi but there was a problem: the banks were only interested in financing shale plays. So with shareholders on board, it decided to sell up and use the leftover cash to move into a new market.

“It was a really tough call because cannabis wasn’t nearly as sexy or acceptable as it now,” explains Lexaria chief executive Chris Bunka.

Within a year, Lexaria had snapped up the rights to a technology called Dehydratech, which is now the backbone of the company.

Essentially it allows cannabidiol (CBD) and other oils to be dehydrated into an odourless, tasteless powder and mixed with xanthan gum, corn flour and other base ingredients which can then be added to foods, drinks and creams.

Another key characteristic of Dehydratech is that it allows drugs and vitamins – in the case of cannabis, CBD – to get into the bloodstream quicker.

Normally, if you were to eat a cannabis-infused food, it might take as long as 40 minutes before you start to feel its effects. With Dehydratech, the CBD gets to work in between 5-15 minutes.

“In short,” Bunka says, “it tastes better, smells better, gets to work quicker and more of it gets into the bloodstream.”

More than 50 patents pending

This is a ready-to-go technology, as well. Initial testing started in 2015 which proved the concept worked and since then various in-animal and in-human tests have been carried out.

“It has been tested more rigorously than most of our competitors and it tests very well,” Bunka says.

Lexaria secured its first patent for the technology back in 2016 and received a second last December. It now has ten awarded in total with a further 53 pending.

Five companies are now using Dehydratech in their products, including the third-largest cannabis chocolate maker in Colorado, 1906 Chocolates, and a Canadian wine and beer maker called Hill Street Beverages.

The plan is for that number to expand quickly, and Bunka reckons there are a couple of levers which will likely be pulled over the next year to enable that.

Local laws will probably be the main growth driver. Even in forward-thinking Canada, edibles are still banned although that will likely change in 2019.

Across the border in the US, more states are also expected to follow the likes of Colorado and California and legalize cannabis.

Add to that some more patent grants and a new US$1mln Kelowna-based laboratory, and next year looks set to be a pivotal one for Lexaria.

“2018 was a good year us, but I think 2019 will be our biggest year yet, no question about it,” claims Bunka.

More than just cannabis, though

While cannabis is the main market right now, Lexaria is thinking long-term, too.

It is developing Dehydratech so it can be used with other things, such as nicotine and painkillers called nonsteroidal anti-inflammatory drugs, or NSAIDs for short.

This, according to Bunka, is arguably what will be the real money-maker company further down the line.

“Everybody is excited about cannabis, but generally speaking, nobody ever dies from using cannabis. On the other hand, between 7,000 and 10,000 people in the US who take NSAIDs die every year, usually through uncontrolled bleeding.

“Out technology is patented for delivering NSAIDs, and because we get so much more effective delivery, in theory, a manufacturer could use a lower dose to give you the same amount of pain relief.”

As for nicotine, Bunka thinks its technology has “monster” potential in this area.

“The same nicotine hit that is delivered in a cigarette, we can deliver in a cup of coffee or in a soft drink or in a pill.

“There’s no smoke, there’s no odour, there’s no taste. You’re offending no one and you’re not going to get cancer because those small amounts of nicotine are not cancerous.”

'Chance to change the world'

Previous rat studies showed that the technology worked, and Lexaria is now gearing up for in-human trials which could start as soon as next year.

A number of these studies will need to be carried out before the technology is commercially ready and the company is looking to partner with industry players to accelerate that.

Still, Bunka is hopeful that the technology will be ready to be submitted for approval for use in nicotine and NSAIDs within two years.

That would mark quite a turnaround for an ex-oil company turned cannabis firm, which could end up commercialising a technology which saves lives.

“It sounds so cliché, but this is our chance to change the world.”

]]>
Thu, 29 Nov 2018 10:00:00 -0500 https://www.proactiveinvestors.com/companies/news/210241/lexaria-bioscience-the-cannabis-company-developing-a-potentially-life-saving-technology-210241.html
<![CDATA[News - Lexaria Bioscience seeks Health Canada application for cannabinoid research lab in British Columbia ]]> https://www.proactiveinvestors.com/companies/news/210060/lexaria-bioscience-seeks-health-canada-application-for-cannabinoid-research-lab-in-british-columbia-210060.html Cannabinoid-focused Lexaria Bioscience Corp. (CNSX:LXX) (OTCMKTS:LXRP) has applied for a Health Canada license to operate a research and development lab at the new headquarters the company is building in Kelowna, British Columbia.

Lexaria said in a press release Monday that the lab will enhance its ability to formulate for analytical purposes various products that may contain cannabinoids or other controlled substances.

READ: Lexaria Bioscience creates four new subsidiaries

The company added that it expects to work on cannabinoid-related formulations as soon as the lab receives its research license. Experimental work on nicotine formulations, non-steroidal anti-inflammatory drugs, vitamins and other bioactive compounds will begin soon after completion of lab construction. The company expects to occupy the new headquarters and lab by the end of January 2019.

Separately, the company said it has appointed Dr Ed Ergenzinger as chief legal officer and senior vice president of innovation. Ergenzinger is a US-licensed patent attorney who also holds a doctorate in neuroscience with concentrations in pharmacology and physiology.

Shares of Lexaria slipped C$0.21 to C$1.35 in Tuesday’s Canadian trading. They were down US$0.16 to US$1.03 on the OTC market.


Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

]]>
Tue, 27 Nov 2018 12:23:00 -0500 https://www.proactiveinvestors.com/companies/news/210060/lexaria-bioscience-seeks-health-canada-application-for-cannabinoid-research-lab-in-british-columbia-210060.html
<![CDATA[News - Lexaria Bioscience granted two new US patents ]]> https://www.proactiveinvestors.com/companies/news/207431/lexaria-bioscience-granted-two-new-us-patents-207431.html Lexaria Bioscience Corp. (OTCQX:LXRP, CSE:LXX), the drug delivery firm, announced Thursday it has been granted two new US patents.

The new patents are related to certain cannabinoid infused beverage compositions utilizing Lexaria's proprietary DehydraTECH process which continue to strengthen the company's intellectual property in the cannabis beverage market.

Lexaria now has six granted patents in the United States and four granted patents in Australia. 

Newly granted patent No. 10,103,225 and No. 10,084,044 provide protection for compositions as well as methods for making the compositions, each of which include the use of both non-psychoactive cannabinoids such as CBD and also psychoactive cannabinoids such as THC.

The company said it is currently pursuing accelerated examination for patent applications in Australia based on these newest U.S. patents and hopes to receive two corresponding Australian patents granted by the end of 2018.

The company said it has more than 50 patent applications filed worldwide across an increasingly diverse range of patent families. 

Shares of Lexaria were up 4.49% at C$2.28 on Thursday. 

]]>
Thu, 18 Oct 2018 21:51:00 -0400 https://www.proactiveinvestors.com/companies/news/207431/lexaria-bioscience-granted-two-new-us-patents-207431.html
<![CDATA[Media files - Lexaria Bioscience continues to show success after restructuring company ]]> https://www.proactiveinvestors.com/companies/stocktube/10842/lexaria-bioscience-continues-to-show-success-after-restructuring-company-10842.html Fri, 12 Oct 2018 14:00:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/10842/lexaria-bioscience-continues-to-show-success-after-restructuring-company-10842.html <![CDATA[Media files - Lexaria Bioscience's drug delivery technology offer products that 'taste better, smell better and act more quickly.' ]]> https://www.proactiveinvestors.com/companies/stocktube/9483/lexaria-bioscience-s-drug-delivery-technology-offer-products-that-taste-better-smell-better-and-act-more-quickly--9483.html Wed, 06 Jun 2018 15:27:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/9483/lexaria-bioscience-s-drug-delivery-technology-offer-products-that-taste-better-smell-better-and-act-more-quickly--9483.html <![CDATA[News - OTCMarkets UPDATE: Casino and cannabis small-cap stocks on the move ]]> https://www.proactiveinvestors.com/companies/news/195786/otcmarkets-update-casino-and-cannabis-small-cap-stocks-on-the-move-195786.html The OTCMarkets were down across the board Wednesday afternoon.

Shares of Poydras Gaming Finance Corp (OTCQX:IGAMF) sunk 22% in afternoon trading after disappointing fourth-quarter results. The Vancouver-based company owns and operates 2,700 slot machines in Oklahoma and Texas casinos. Revenue increased 1% to US$4.1mln compared to US$4.0mln in the same quarter last year. The company changed CEOs earlier this month and changed its name to Integrity Gaming Corp at the beginning of 2018.

Galaxy Gaming Inc (OTCQB:GLXZ) shares jumped more than 17% after announcing a complete debt refinancing. The company develops, manufactures, and distributes casino table games. The credit agreements allows for US$12mln in borrowing capacity, with US$11mln via a five-year loan and US$1mln in a one-year revolving credit facility. The company also announced a stock buyback of up to US$1mln worth of shares.

Biotech company Lexaria Bioscience Corp (OTCQX:LXRP) shares are up more than 3% after announcing a licensing agreement with California cannabis beverage maker GP Holdings LLC. The Vancouver-based company is providing its patented DehydraTECH technology that allows for high absorption of cannabis.

Kaya Holdings, Inc (OTCQB:KAYS) has opened its fourth legal marijuana dispensary in Oregon. Located in a strip mall alongside fast food chains like Popeye’s and Carl’s Jr., the stores sell a variety of cannabis and cannabis-infused products like blood orange white chocolate bars and body care products like pain relief topical oils. The stores also offer home delivery of the products within Salem, Oregon. Shares were up 5.7% in afternoon trading.

]]>
Wed, 25 Apr 2018 14:44:00 -0400 https://www.proactiveinvestors.com/companies/news/195786/otcmarkets-update-casino-and-cannabis-small-cap-stocks-on-the-move-195786.html
<![CDATA[News - Lexaria jumps on "excellent" oil production rates at Belmont Lake oil well ]]> https://www.proactiveinvestors.com/companies/news/103274/lexaria-jumps-on-excellent-oil-production-rates-at-belmont-lake-oil-well-56843.html Lexaria (CNSX:LXX), which explores, acquires, and develops oil and gas properties,  advanced in midday trades after posting what it described as "excellent oil production rates" at the new PPF-12-7 oil well at Belmont Lake, in Mississippi.

The well is now flowing and selling oil, the Vancouver, British Colombia-based company said in a statement today.

Shares surged 26 percent to 12 Canadian cents at 1:04 p.m. in Toronto. The stock has tripled so far this year.

As of Sept. 12, the well was producing 120 barrels of oil per day on a 12/64th choke. 

For Sept. 13, it produced 119 barrels of oil per day on an 11/64th choke; and on Sept 14 it produced 119 bo/d on a 10/64th choke. 

No formation water has been produced and flowing pressures increased each day as choke sizes were reduced, indicating healthy reservoir pressures, the company said.

This is one of the highest flow rates ever for a Belmont Lake well, and more than meets Lexaria's expectations. The 12-7 well is located further east than any other existing well in Belmont Lake field, further expanding the producing boundaries of the field which are still undetermined.

The operator and owners intend to restrict this well to 90 barrels of oil per day for the intermediate term on an even more restricted choke, and to monitor the well over time to optimize production in the short and long terms, according to the statement.  

Lexaria said that this allows for more prudent operation of the well and field over time, as many Frio-formation wells can produce oil for as long as 10 or 15 years.

Although earlier sidewall core analysis indicated 19-20 feet (true vertical depth) of oil bearing pay, only the upper 8 feet of the well was perforated in order to stay above the oil/water contact zone.

"Taken within the context of this conservative perforation technique and the restriction from the small choke size, I view the oil production rates from this well as even more positive,"  Chris Bunka, president of Lexaria, said in the statement.

Lexaria retains a 42 percent working interest in the producing 12-1 and 12-3 wells; a 50 percent working interest in the suspended 12-4 and 12-5 wells; and a 13.3 percent working interest in the 12-7 well. 

 

 

 

]]>
Tue, 16 Sep 2014 14:42:00 -0400 https://www.proactiveinvestors.com/companies/news/103274/lexaria-jumps-on-excellent-oil-production-rates-at-belmont-lake-oil-well-56843.html
<![CDATA[News - Lexaria surges on deal for second marijuana facility ]]> https://www.proactiveinvestors.com/companies/news/101503/lexaria-surges-on-deal-for-second-marijuana-facility-54351.html Lexaria Corp. (OTCQB:LXRP) (CSE:LXX) has signed a deal for its second marijuana production facility in Canada with Huntington Property Group, an Ottawa-based real estate developer. 

Shares rocketed 50% higher on Tuesday, to 30 Canadian cents, pushing year-to-date gains to 750%. 

The facility, which is located in eastern Ontario, is spread over 80,000 square feet, and is expected to be completed through a multi-phase development program. Lexaria will be the operator, and would own 100% rights by paying all initial and ongoing expenses tied to the project, with no overrides or royalties due to any parties, it said.

Lexaria is issuing no shares whatsoever in order to acquire the rights to the facility, according to the company's statement released Tuesday Morning.

An initial 10-year lease will be given, with options to renew the lease for an additional 16 years. 

Under the preliminary letter of intent agreement, Lexaria also plans to raise up to $3.0 million through vendor financing. Lexaria said that a number of investors, including the building owner, have agreed to invest up to $2.0 million in the company, which will be used to build out the facility. Meanwhile, the vendor is contribuing up to $1 million in cash which will be directed towards the conversion costs required to renovate for the marijuana production operation.

The company said this deal was signed just six weeks after its first marijuana production facility was announced with its joint venture partner Enertopia (CSE:TOP), as part of its efforts to mitigate potential losses by operating under more than one Health Canada marijuana production license.

Lexaria stressed in its release that the new facility "in no way" reduces its commitment to its greater Toronto area operations, which continues to advance separately. 

No lease payments are scheduled to begin until the municipality grants its approval of the building zoning for marijuana production, Lexaria said, with an application currently being prepared. An approval is expected within 90 days.

Just over six weeks since the new Federal rules kicked in in Canada to regulate medical marijuana production, companies are moving quickly to assert themselves in a market that is set for explosive growth by anyone's standards. 

The introduction of the Marijuana for Medical Purposes Regulations (MMPR) last month makes it so that the only legal access to marijuana for medical use is now exclusively through producers that are licensed under the new regulations. Health Canada predicts the burgeoning industry will be worth some $1.3 billion by 2024, and that the number of users could increase 10-fold within five years. 

So far, only 12 licenses have been granted to date under MMPR, with many junior companies identifying a shortage given the expected growth in medical marijuana users in Canada over the next decade. 

]]>
Tue, 27 May 2014 11:11:00 -0400 https://www.proactiveinvestors.com/companies/news/101503/lexaria-surges-on-deal-for-second-marijuana-facility-54351.html